Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

The Institute of Cancer Research

Headquarters: London, United Kingdom
Year Founded: 1909
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Aug 2, 2024
Distillery Therapeutics

Inhibiting NBS1 lactylation for chemotherapy resistance

BioCentury | Aug 1, 2024
Distillery Therapeutics

RIPK1 PROTAC for cancer

BioCentury | Oct 20, 2023
Discovery & Translation

Targeted protein degrader design insights; plus Long COVID, obesity and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 7, 2022
Distillery Therapeutics

Targeting USP25 for pancreatic cancer

BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Versant-built start-up finds targets, compounds for protein degradation via structural biology and proteomics
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

BioCentury’s roundup of preclinical news
BioCentury | Oct 16, 2019
Company News

AI play Healx raises $56M to repurpose drugs for rare disease

How Healx is tackling rare diseases using AI and input from patient groups
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
Items per page:
1 - 10 of 130